Active substance
Cinnarizine
- SFDA 3
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| STUGERON 25MG TAB | 25 mg | Tablet · Oral use | 50 Tablet Container | SAR 10.85 | Generic · Prescription | JANSSEN-CILAG | Valid |
| CEREPAR | 75 mg | Tablet · Oral use | 50 Blister | SAR 20.55 | NCE · Prescription | MERCKLE | Invalid · Not Marketed |
| CEREPAR | 75 mg | Tablet · Oral use | 20 Blister | SAR 8.20 | NCE · Prescription | MERCKLE | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
VERTIGO - MOTION SICKNESS
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Cinnarizine 15mg tablets | £3.60 | 84 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Combinations containing Cinnarizine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.